Trade Grifols, S.A. - GRLS CFD

Trading Conditions

• Type: CFD
• Spread: 0.08
• Long position overnight funding adjustment: -0.01660%
• Short position overnight funding adjustment: -0.00562%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: EUR
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Spain
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 9.24
• Open: 9.23
• 1-Year Change: -1.28%
• Day's Range: 9.14 - 9.3

What is Grifols (GRLS)?

Grifols is a global healthcare company headquartered in Spain, specializing in the production of plasma-derived medicines and hospital supplies. It operates in the biopharmaceutical sector, focusing on therapies for rare, chronic, and complex conditions. Grifols collects plasma through a network of donation centers and processes it to manufacture a range of products including immunoglobulins, albumin, and coagulation factors. The company also develops diagnostic systems and hospital equipment. Grifols has a significant international presence and invests in research and development to advance medical treatments and technologies. Its operations adhere to stringent regulatory standards and quality controls within the healthcare industry.

Grifols Stock Price Today: Live Overview

The price today is shaped by recent market activity, with Grifols currently trading at €9.25. During the session, it has moved between €9.11 and €9.31, showing a daily change of 0%.

FAQ: Grifols (GRLS)

What is the current price of GRLS stock?

Grifols is currently trading at €9.25.

Does GRLS pay dividends?

Grifols pays dividends via cash distributions (if applicable).

Does GRLS have a formal corporate presence or regional headquarters in the UAE?

Grifols operates in the UAE through partners and distributors without an official regional office.

What is GRLS best known for?

Grifols is most famous for its plasma-derived medicines and diagnostic products.

What assets are typically shown together with GRLS?

Commonly shown alongside GRLS: Johnson & Johnson, Sanofi, Eli Lilly & Co